Please tell us about your experience. What are some of the recent advances happening in the Graft Versus Host Disease space?

How often is GvHD associated with stem cell transplants vs organ transplants?

Please tell us about the underlying mechanism of the disease, and walk us through EQ001’s interaction in regards to the alloimmunity of the donor cells? 

• How does it reduce the synthesis of pro-inflammatory cytokines? 
• What are its modulation properties on effector T cells, or Teff cells ?

What difference is there between EQ001 and Biocon’s Itolizumab (trade name Alzumab), both CD6 inhibitors.

• What are some of the pros and cons that you can name?

What is your impression of the Results from Equate Phase 1b/2 on Inhibiting the CD6-ALCAM pathway?

What can we expect from the initial data, due in the second half of the year, and how would it impact further development?

How can EQ001 impact future iGVHD chronic GVHD prevention?

What advantage does EQ001 possess in terms of delivery method vs standard of practice, as subcutaneous injection or IV as it is both available in collaboration with manufacturer Biocon?

Can you please compare ALZUMAb, being produced in an NS0 cell line and available as either intravenous, or IV vs EQ001 identical monoclonal antibody sequence produced in a Chinese hamster ovary cell line?